Table 2.
Measures of kidney function across groups
| NM-OSA | Insomnia-SD | MS-OSA | COMISA-SD | p | |
|---|---|---|---|---|---|
| N | 203 | 104 | 242 | 183 | |
| Serum creatinine (µmol/L) | 76 (66.0, 88.0) | 77.0 (63.0, 86.0) | 83.5*,† (72.0, 95.0) | 83*,† (70.0, 93.5) | <.001 |
| eGFR (mL/min/1.73 m2) | 91 (78, 98) | 89 (77, 98) | 84* (70, 97) | 85 (72, 96) | .016 |
| Urine albumin (mg/L)# | 7.7 (5.0, 12.8) | 9.0 (6.0, 15.1) | 9.5* (5.0, 22.8) | 10.0* (5.0, 34.5) | .010 |
| Urine creatinine (mmol/L) | 11.0 (6.4, 15.6) | 11.8 (7.0, 16.9) | 11.8 (7.1, 16.5) | 11.0 (7.5, 16.2) | .844 |
| ACR (mg/mmol) | 0.8 (0.5, 1.6) | 0.9 (0.5, 1.5) | 1.1 (0.5, 2.2) | 1.0 (0.5, 2.9) | .072 |
Median (interquartile range); p value = Kruskal–Wallis H. COMISA-SD, comorbid insomnia and OSA with short sleep duration; MS-OSA, moderate-to-severe OSA, no insomnia. Bold typeface highlights the P values that are significant between the groups.
#Urine albumin was below detectable limits in 96 participants.
*p < .05 versus NM-OSA (no/mild OSA, no insomnia).
† p < .05 versus Insomnia-SD (insomnia with short sleep duration).